Compare Glenmark Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PIRAMAL ENTERPRISES GLENMARK PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 14.0 11.7 118.9% View Chart
P/BV x 1.8 0.8 221.4% View Chart
Dividend Yield % 0.6 2.9 19.6%  

Financials

 GLENMARK PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
PIRAMAL ENTERPRISES
Mar-19
GLENMARK PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs7123,303 21.5%   
Low Rs4841,797 26.9%   
Sales per share (Unadj.) Rs349.6716.5 48.8%  
Earnings per share (Unadj.) Rs32.879.7 41.1%  
Cash flow per share (Unadj.) Rs44.3107.9 41.1%  
Dividends per share (Unadj.) Rs2.0028.00 7.1%  
Dividend yield (eoy) %0.31.1 30.5%  
Book value per share (Unadj.) Rs198.61,477.5 13.4%  
Shares outstanding (eoy) m282.17184.45 153.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.73.6 48.0%   
Avg P/E ratio x18.232.0 57.0%  
P/CF ratio (eoy) x13.523.6 57.0%  
Price / Book Value ratio x3.01.7 174.3%  
Dividend payout %6.135.1 17.4%   
Avg Mkt Cap Rs m168,625470,292 35.9%   
No. of employees `00012.07.8 153.9%   
Total wages/salary Rs m20,56122,504 91.4%   
Avg. sales/employee Rs Th8,196.016,899.4 48.5%   
Avg. wages/employee Rs Th1,708.12,877.7 59.4%   
Avg. net profit/employee Rs Th768.51,879.9 40.9%   
INCOME DATA
Net Sales Rs m98,655132,153 74.7%  
Other income Rs m2,0813,128 66.5%   
Total revenues Rs m100,736135,281 74.5%   
Gross profit Rs m15,85866,290 23.9%  
Depreciation Rs m3,2595,202 62.7%   
Interest Rs m3,34644,097 7.6%   
Profit before tax Rs m11,33520,119 56.3%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7568,611 43.6%   
Profit after tax Rs m9,25014,701 62.9%  
Gross profit margin %16.150.2 32.0%  
Effective tax rate %33.142.8 77.4%   
Net profit margin %9.411.1 84.3%  
BALANCE SHEET DATA
Current assets Rs m66,968122,742 54.6%   
Current liabilities Rs m40,211310,810 12.9%   
Net working cap to sales %27.1-142.3 -19.1%  
Current ratio x1.70.4 421.7%  
Inventory Days Days8323 361.2%  
Debtors Days Days8139 209.1%  
Net fixed assets Rs m33,322116,904 28.5%   
Share capital Rs m282369 76.5%   
"Free" reserves Rs m55,770272,161 20.5%   
Net worth Rs m56,052272,530 20.6%   
Long term debt Rs m35,738270,196 13.2%   
Total assets Rs m132,888856,261 15.5%  
Interest coverage x4.41.5 301.3%   
Debt to equity ratio x0.61.0 64.3%  
Sales to assets ratio x0.70.2 481.0%   
Return on assets %9.56.9 138.0%  
Return on equity %16.55.4 305.9%  
Return on capital %17.812.4 143.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99815,200 414.5%   
Fx outflow Rs m22,8594,889 467.6%   
Net fx Rs m40,14010,312 389.3%   
CASH FLOW
From Operations Rs m13,242-115,975 -11.4%  
From Investments Rs m-6,990-8,265 84.6%  
From Financial Activity Rs m-7,387107,525 -6.9%  
Net Cashflow Rs m-2,971-16,650 17.8%  

Share Holding

Indian Promoters % 48.3 52.9 91.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.0 172.5%  
FIIs % 34.4 26.6 129.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 16.5 63.6%  
Shareholders   56,727 93,274 60.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FULFORD INDIA  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 224 Points Higher; Realty and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

Get Rich as the
Market Rebounds from Covid-19

Coronavirus Rebound
Get this special guide, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


May 29, 2020 03:35 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS